New Dual Mode Gadolinium Nanoparticle Contrast Agent for Magnetic Resonance Imaging

Background Liposomal-based gadolinium (Gd) nanoparticles have elicited significant interest for use as blood pool and molecular magnetic resonance imaging (MRI) contrast agents. Previous generations of liposomal MR agents contained gadolinium-chelates either within the interior of liposomes (core-encapsulated gadolinium liposomes) or presented on the surface of liposomes (surface-conjugated gadolinium liposomes). We hypothesized that a liposomal agent that contained both core-encapsulated gadolinium and surface-conjugated gadolinium, defined herein as dual-mode gadolinium (Dual-Gd) liposomes, would result in a significant improvement in nanoparticle-based T1 relaxivity over the previous generations of liposomal agents. In this study, we have developed and tested, both in vitro and in vivo, such a dual-mode liposomal-based gadolinium contrast agent. Methodology/Principal Findings Three types of liposomal agents were fabricated: core-encapsulated, surface-conjugated and dual-mode gadolinium liposomes. In vitro physico-chemical characterizations of the agents were performed to determine particle size and elemental composition. Gadolinium-based and nanoparticle-based T1 relaxivities of various agents were determined in bovine plasma. Subsequently, the agents were tested in vivo for contrast-enhanced magnetic resonance angiography (CE-MRA) studies. Characterization of the agents demonstrated the highest gadolinium atoms per nanoparticle for Dual-Gd liposomes. In vitro, surface-conjugated gadolinium liposomes demonstrated the highest T1 relaxivity on a gadolinium-basis. However, Dual-Gd liposomes demonstrated the highest T1 relaxivity on a nanoparticle-basis. In vivo, Dual-Gd liposomes resulted in the highest signal-to-noise ratio (SNR) and contrast-to-noise ratio in CE-MRA studies. Conclusions/Significance The dual-mode gadolinium liposomal contrast agent demonstrated higher particle-based T1 relaxivity, both in vitro and in vivo, compared to either the core-encapsulated or the surface-conjugated liposomal agent. The dual-mode gadolinium liposomes could enable reduced particle dose for use in CE-MRA and increased contrast sensitivity for use in molecular imaging.

[1]  Dariusch R Hadizadeh,et al.  Peripheral MR angiography with blood pool contrast agent: prospective intraindividual comparative study of high-spatial-resolution steady-state MR angiography versus standard-resolution first-pass MR angiography and DSA. , 2008, Radiology.

[2]  P. Cullis,et al.  Liposomal Gd-DTPA: effect of encapsulation on enhancement of hepatoma model by MRI. , 1989, Magnetic resonance imaging.

[3]  P A Narayana,et al.  High-resolution vascular imaging of the rat spine using liposomal blood pool MR agent. , 2007, AJNR. American journal of neuroradiology.

[4]  M. Port,et al.  How to Compare the Efficiency of Albumin-Bound and Nonalbumin-Bound Contrast Agents In Vivo: The Concept of Dynamic Relaxivity , 2005, Investigative radiology.

[5]  Ananth Annapragada,et al.  Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Ananth Annapragada,et al.  T1 relaxivity of core-encapsulated gadolinium liposomal contrast agents--effect of liposome size and internal gadolinium concentration. , 2008, Academic radiology.

[7]  Michael Scott,et al.  Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics , 2007, International journal of nanomedicine.

[8]  Martin Requardt,et al.  Contrast‐enhanced MR angiography of the run‐off vasculature: Intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine , 2003, Journal of magnetic resonance imaging : JMRI.

[9]  Janos Szebeni,et al.  Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. , 2005, Toxicology.

[10]  R. Scotti,et al.  High relaxivity contrast agents in MR angiography of the carotid arteries , 2006, European radiology.

[11]  Martin R Prince,et al.  3D contrast‐enhanced MR angiography , 2007, Journal of magnetic resonance imaging : JMRI.

[12]  Zahi A Fayad,et al.  Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. , 2004, Journal of the American Chemical Society.

[13]  Yi Qi,et al.  Four‐dimensional MR microscopy of the mouse heart using radial acquisition and liposomal gadolinium contrast agent , 2008, Magnetic resonance in medicine.

[14]  Mitchell D Schnall,et al.  Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessing Tumor Vascularity and Vascular Effects of Targeted Therapies in Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[15]  Sheng-Kwei Song,et al.  Improved molecular imaging contrast agent for detection of human thrombus , 2003, Magnetic resonance in medicine.

[16]  R. Bellamkonda,et al.  Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. , 2009, Biomaterials.

[17]  Hisataka Kobayashi,et al.  Nano-sized MRI contrast agents with dendrimer cores. , 2005, Advanced drug delivery reviews.

[18]  Xiaoping Hu,et al.  Long‐circulating liposomal contrast agents for magnetic resonance imaging , 2006, Magnetic resonance in medicine.

[19]  P. Cullis,et al.  Liposomal Gd-DTPA: preparation and characterization of relaxivity. , 1989, Radiology.

[20]  D. Bilecen,et al.  MR angiography with blood pool contrast agents , 2007, European Radiology.

[21]  Efstathios Karathanasis,et al.  Tumor Vascular Permeability to a Nanoprobe Correlates to Tumor-Specific Expression Levels of Angiogenic Markers , 2009, PloS one.

[22]  K. Maruyama,et al.  Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. , 1999, International journal of pharmaceutics.

[23]  K. Nicolay,et al.  A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. , 2004, Bioconjugate chemistry.

[24]  King Li,et al.  Paramagnetic polymerized liposomes as new recirculating MR contrast agents , 1995, Journal of magnetic resonance imaging : JMRI.

[25]  M. Knopp,et al.  Functional tumor imaging with dynamic contrast‐enhanced magnetic resonance imaging , 2003, Journal of magnetic resonance imaging : JMRI.

[26]  Justin Saul,et al.  Folate targeting of drug carriers: a mathematical model. , 2005, Journal of controlled release : official journal of the Controlled Release Society.